Literature DB >> 1691171

Regulation of 5-phosphoribosyl 1-pyrophosphate and of hypoxanthine uptake and release in human erythrocytes by oxypurine cycling.

P A Berman1, L Human.   

Abstract

Uptake and release of purines by red blood cells has been shown to be markedly sensitive to changes in pH, inorganic phosphate (Pi), and oxygen concentration (Berman, P., Black, D., Human, L., and Harley, E. (1988) J. Clin. Invest. 82, 980-986). The mechanism of this regulation has been further studied. We have shown that incubation of red cells in medium containing xanthine oxidase rapidly and completely depletes intracellular hypoxanthine and causes accumulation of 5-phosphoribosyl 1-pyrophosphate (PRPP) at physiological Pi concentrations. Hypoxanthine release from intracellular IMP is strictly dependent on PRPP depletion, induced by either alkalinizing the cells or by adding excess adenine. Xanthine oxidase abolishes this dependence. Oxygen depletion enhances adenine uptake and prevents hypoxanthine release. The results suggest that hypoxanthine release is governed by PRPP-dependent recycling of hypoxanthine to IMP. We propose that PRPP accumulation in red cells is regulated by a substrate cycle, comprising hypoxanthine, IMP, and inosine. Cycle flux is controlled by Pi inhibition and 2,3-bisphosphoglycerate activation of purine-5'-nucleotidase, which converts IMP to inosine. Oxypurine cycling may account for the sensitive control of purine uptake and release by changes in pH and oxygen tension that occur physiologically.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691171

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Accelerated degradation of adenine nucleotide in erythrocytes of patients with chronic renal failure.

Authors:  M Marlewski; R T Smolenski; M Szolkiewicz; Z Aleksandrowicz; B Rutkowski; J Swierczynski
Journal:  Mol Cell Biochem       Date:  2000-10       Impact factor: 3.396

Review 2.  IFN-induced cell-autonomous immune mechanisms in the control of intracellular protozoa.

Authors:  Sini Skariah; Ali A Sultan; Dana G Mordue
Journal:  Parasitol Res       Date:  2022-04-18       Impact factor: 2.383

3.  The accumulation of mercaptopurine metabolites in age fractionated red blood cells.

Authors:  A Rostami-Hodjegan; L Lennard; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

4.  Xanthine oxidase inhibits growth of Plasmodium falciparum in human erythrocytes in vitro.

Authors:  P A Berman; L Human; J A Freese
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

5.  Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia.

Authors:  L Lennard; J P Hale; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

6.  Purine salvage pathways among Borrelia species.

Authors:  Jonas Pettersson; Merry E Schrumpf; Sandra J Raffel; Stephen F Porcella; Cyril Guyard; Kevin Lawrence; Frank C Gherardini; Tom G Schwan
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

7.  Recent advances in structure and function of cytosolic IMP-GMP specific 5'-nucleotidase II (cN-II).

Authors:  Piero Luigi Ipata; Maria Grazia Tozzi
Journal:  Purinergic Signal       Date:  2006-06-29       Impact factor: 3.765

8.  Comparison of human erythrocyte purine nucleotide metabolism and blood purine and pyrimidine degradation product concentrations before and after acute exercise in trained and sedentary subjects.

Authors:  Wioleta Dudzinska; M Suska; A Lubkowska; K Jakubowska; M Olszewska; K Safranow; D Chlubek
Journal:  J Physiol Sci       Date:  2017-04-21       Impact factor: 2.781

9.  Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells.

Authors:  M Inaba; J Mitsuhashi; H Sawada; N Miike; Y Naoe; A Daimon; K Koizumi; H Tsujimoto; M Fukushima
Journal:  Jpn J Cancer Res       Date:  1996-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.